Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
31.34
+0.78 (2.55%)
Mar 17, 2026, 12:36 PM EDT - Market open
Capricor Therapeutics Employees
Capricor Therapeutics had 160 employees as of December 31, 2024. The number of employees increased by 58 or 56.86% compared to the previous year.
Employees
160
Change (1Y)
58
Growth (1Y)
56.86%
Revenue / Employee
n/a
Profits / Employee
-$656,525
Market Cap
1.43B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 160 | 58 | 56.86% | 160 | 0 |
| Dec 31, 2023 | 102 | 28 | 37.84% | 101 | 1 |
| Dec 31, 2022 | 74 | 26 | 54.17% | 74 | 0 |
| Dec 31, 2021 | 48 | 22 | 84.62% | 48 | 0 |
| Dec 31, 2020 | 26 | 10 | 62.50% | 26 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ardelyx | 489 |
| Vir Biotechnology | 367 |
| Biohaven | 274 |
| Zenas BioPharma | 130 |
| Olema Pharmaceuticals | 122 |
| Pharvaris | 118 |
| AtaiBeckley | 99 |
| Rapport Therapeutics | 84 |
CAPR News
- 3 days ago - Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel - Seeking Alpha
- 3 days ago - Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates - Benzinga
- 4 days ago - Capricor Therapeutics, Inc. (CAPR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 days ago - Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy - GlobeNewsWire
- 7 days ago - Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review - Benzinga
- 7 days ago - Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA - GlobeNewsWire
- 7 days ago - What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? - Benzinga